AM–Pharma is a biopharmaceutical company developing proprietary recombinant human Alkaline Phosphatase (AP) therapeutics, which have the potential to transform the treatment prospects for patients with chronic or life-threatening inflammatory diseases.
AM-Pharma discovered that AP can protect organs against inflammation and tissue damage. While this enzyme is found in many cells of the body, it is present at reduced levels in certain diseases including Acute Kidney Injury (AKI) and Ulcerative Colitis (UC).
Previously, the company developed and successfully tested a bovine form of AP in three phase II trials in patients with sepsis, AKI and UC.
AM-Pharma has since developed and manufactured a proprietary and fully human recombinant form of AP, known as recAP. In a Phase I study in healthy volunteers recAP showed a clean safety profile and favorable pharmacological properties.
Recently, the company started a Phase II trial in patients diagnosed with sepsis-associated acute kidney injury (SA-AKI). With an estimated two million AKI patients in the western world, no current treatments available, and an estimated 10 billion dollar healthcare cost for AKI supportive care in the US, a therapy would be very welcome.
Acute Kidney Injury is an acute inflammation of the kidney, which results in kidney damage and a rapid loss of kidney function and often leads to dialysis. Depending on the severity of kidney failure, the mortality rate is as high as 80%.There are currently no approved drugs for disease treatment. Read more.
Inflammatory Bowel Disease is a group of inflammatory conditions of the colon and small intestine, The major types include Crohn's disease and Ulcerative Colitis. There are two biologics approved for treating ulcerative colitis, but there remains a clear need for a therapy that is both safe, efficacious over time and convenient to use. Read more.